This document was drafted on the basis of the Transparency Committee opinion, French National Authority for Health, dated 27 February 2019.
It found insufficient clinical benefit of ESMYA* for the treatment of uterine fibroids to justify reimbursement. They conclude:
- The actual clinical benefit of ESMYA is insufficient to justify its reimbursement by public funding in its two indications.
- Not approved for non-hospital pharmacy reimbursement or for hospital treatment.
*ESMYA - (ulipristal acetate), progesterone receptor modulator.